浸入科技 IMMR 深 滬
等待開盤 08-25 09:30:00 美东时间
7.06
+0.120
+1.73%
華盛通- 最 高7.17
- 今 開6.98
- 成交量 65.11万股
- 最 低 6.97
- 昨 收 6.94
- 總市值 2.29亿
- 52周最高 10.385
- 市盈率 靜 6.76
- 換手率 2.01%
- 52周最低 6.38
- 委 比 -3.29%
- 總股本 3239.64万
- 歷史最高 16.97
- 量 比 1.50
- 振 幅 2.88%
- 歷史最低 3.415
- 每 手 1
- 風險率 1.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immersion Faces Nasdaq Filing Compliance Deadline
The latest update is out from Immersion ( ($IMMR) ). On August 20, 2025, Immers...
08-23 04:48
Immersion Corporation receives delinquency compliance alert notice from Nasdaq
Immersion Corporation (NASDAQ:IMMR) has received a delinquency compliance alert notice from Nasdaq notifying the company that due to the its failure to timely file its annual report on Form 10-K for t...
08-23 04:07
Immersion Announces Quarterly Cash Dividend Declaration
Immersion ( ($IMMR) ) has provided an announcement. On July 8, 2025, Immersion ...
07-09 04:56
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
Immuneering Corporation reported positive Phase 2a data for atebimetinib in combination with modified Gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The treatment showed 94% overall survival (OS) and 72% progression-free survival (PFS) at 6 months, with a 39% overall response rate and 81% disease control rate. Atebimetinib demonstrated a favorable tolerability profile. The company plans a pivotal trial for 2026 and will host...
06-17 10:00
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
<p>Immuneering Corporation announced it will host a conference call and live webcast on June 17, 2025, at 8:00 am ET, to update on its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The webcast will be available on the company's Investor Relations website. IMM-1-104 is an oral, once-daily MEK inhibitor targeting MAPK pathway-driven tumors like pancreatic cancer. For more information, visit www.immuneering.c...
06-16 12:00
Immuneering to Present at the Jefferies Global Healthcare Conference
**Immuneering Corporation to Present at Jefferies Global Healthcare Conference** Immuneering Corporation, a clinical-stage oncology company focused on developing effective and well-tolerated cancer therapies, will present at the Jefferies Global Healthcare Conference on June 5, 2025. The presentation will include a company overview, pipeline updates, and business strategy discussions. Key executives, including CEO Ben Zeskind, CMO Igor Matushan...
05-29 12:00
美股大行评级 | 花旗：首予BioNTech SE(BNTX)"买入"评级，目标价145美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107226114384474112.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Zevra Therapeutics(ZVRA)"买入"评级，目标价从23美元升至25美元</p> <p>• Benchmark：维持E W Scripps(SSP)"买入"评级，目
03-14 09:45
Immersion Non-GAAP EPS of $0.63 beats by $0.08, revenue of $474.76M beats by $338.7M
Immersion press release (NASDAQ:IMMR): Q3 Non-GAAP EPS of $0.63 beats by $0.08. Revenue of $474.76M (compared to $9.5 million in the three months ended September 30, 2023) beats by $338.7M. More on Im...
03-12 20:39
Immersion Q3 EPS $0.47, Sales $474.76M
Immersion (NASDAQ:IMMR) reported quarterly earnings of $0.47 per share. The company reported $474.76 million in sales this quarter.
03-12 20:34
美股大行评级 | 潜在升幅410%！TransCode Therapeutics获机构大幅上调目标价至20美元
<span> <meta content="no-referrer" name="referrer"></span><img src="https://r.hstong.com/public/cms/images/2024/12/19/20241219084201089.png" referrerpolicy="no-referrer"><figure class="table" style="overflow-x: scroll;"> <table> <tbody> <tr> <td>标的</td> <td>代码</td> <td>评级</td> <td>目标价</td> <td>当前价</td> <td>潜在涨跌幅</td> <td>机构名称</td> </tr> <tr> <td>TransCode Therapeutics Inc Ordinary Shares</td> <td
2024-12-19 09:43
